The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Background Lymphocyte-activation gene 3 (LAG3) is a recently discovered immune
checkpoint molecule that has been linked to immunosuppression and the advancement of …

Objective To find out how bacterial lung infections (BLI) affect the effectiveness of therapy
and the rate of pneumonia caused by pneumonia related to checkpoint inhibitors (CIP) in …

We report the generation of a novel anti-LAG-3/TIGIT bispecific IgG4 antibody, ZGGS15, and
evaluated its anti-tumor efficacy in mouse models as monotherapy or in combination with a …

Simple Summary Cutaneous squamous cell carcinomas (SCCs) are the most common
tumors in patients suffering from the genetic disorder epidermolysis bullosa (EB). These …

Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs),
immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the …

Anti-TNF-α therapy fails in 30% of patients, where TNF-α may not be the key causative factor
in these patients. We developed a bispecific single-domain antibody block TNF-α and VEGF …

In recent years, remarkable strides have been made in the field of immunotherapy, which
has emerged as a standard treatment for many cancers. As a kind of immunotherapy drug …

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the first and second
most common primary liver cancer (PLC). For decades, systemic therapies consisting of …

It is well-established that tumor antigens and molecules expressed and secreted by cancer
cells trigger innate and adaptive immune responses. These two types of anti-tumor immunity …